Objective To describe the pharmacokinetics of midazolam, a water‐soluble benzodiazepine
with a short half‐life, in critically ill neonates. Hypothesis Midazolam clearance is reduced in …

Background Midazolam, a benzodiazepine, is finding expanded use in neonatal intensive
care units. We studied the pharmacokinetics and metabolism of midazolam after a single …

OBJECTIVE: To determine the steady-state plasma concentrations of midazolam in critically
ill infants and children. DESIGN: Prospective uncontrolled study conducted over 18 months …

Background Midazolam is used widely as a sedative to facilitate mechanical ventilation. This
prospective study investigated the population pharmacokinetics of midazolam in very …

Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and
children. An IV bolus (0.2 mg· kg− 1) immediately followed by continuous infusion of 0.06 …

Objective: To evaluate the effects of intravenous midazolam on haemodynamic variables
and cerebral blood flow velocity (CBFV) and to determine the pharmacokinetics using a …

Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and
children. An IV bolus of midazolam 0.2 mg· kg− 1 was administered to 10 critically ill …

Aims To characterize the pharmacokinetics and metabolism of oral midazolam in 15 preterm
infants. Methods After an oral dose (0.1 mg kg− 1), blood was drawn up to 24 h after …

Midazolam is a parenteral benzodiazepine with sedative, amnesic, anxiolytic, muscle
relaxant and anticonvulsant properties. The drug exerts its clinical effect by binding to a …

Midazolam is a benzodiazepine with rapid onset of action and short duration of effect. In
healthy neonates the half‐life (t1/2) and the clearance (Cl) are 3.3‐fold longer and 3.7‐fold …